Skip to main content
. Author manuscript; available in PMC: 2013 May 9.
Published in final edited form as: Leukemia. 2008 Jan 17;22(4):850–855. doi: 10.1038/sj.leu.2405091

Figure 1.

Figure 1

Overall survival (OS) (a) and event-free survival (EFS) (b) for all Total Therapy protocols from first transplant according to the presence of cytogenetic abnormalities (CA) detected at baseline or pretransplant. Outcomes were superior in the absence of CA at both time points, followed by an intermediate prognosis in patients with CA detected only at baseline, whereas those with detectable CA pretransplant had the poorest outcomes regardless of CA presence at baseline. (c and d) Show OS and EFS data for TT2 with similar differences as in the whole group. In the case of TT1, patients presenting without CA at both time points fared better than those with CA at any time point (e and f).